Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion

被引:13
作者
Nord, LD
Stolfi, RL
Alfieri, AA
Netto, G
Reuter, V
Sternberg, SS
Colofiore, JR
Koutcher, JA
Martin, DS
机构
[1] CATHOLIC MED CTR,DEPT CANC RES,WOODHAVEN,NY 11421
[2] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
[3] VA HOSP,NORTHPORT,NY
关键词
methylmercaptopurine riboside; N-(phosphonacetyl)-L-aspartic acid; 6-aminonicotinamide; mammary carcinoma; tumor regression; iodotubercidin; apoptosis; fluorouracil;
D O I
10.1007/s002800050674
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The drug combination N-(phosphonacetyl)-L-aspartic acid (PALA). methylmercaptopurine riboside (MMPR) and 6-aminonicotinamide (6AN). referred to as PMA. induces regressions of advanced CD8F1 murine mammary carcinomas in vivo. We demonstrated that CD8F1 tumor regressions were preceded by the appearance of apoptotic bodies, as observed by microscopic examination of morphology and TUNEL end-labeling, and fragmentation of DNA into nucleosomal ''ladder'' patterns. These indications of apoptosis were present as early as 6 h after simultaneous administration of MMPR and 6AN and further increased by over fivefold during the next 3 to 6 h. then remained at 7 to 12.8% (0.6 to 2.4% in saline-treated controls) of the cell population for at least 24 h after MMPR + 6AN administration. The 5'-phosphate derivative of MMRP. MMPR-5P, which inhibits de novo purine biosynthesis. was present at a ''steady-state'' level. and significant (40%) depletion of ATP had occurred by 3 h and both of these events preceded the onset of apoptosis. In addition. MMPR-SP was retained in CD8F1 tumors at a high level over a prolonged period (>96 h) even as rumors were undergoing regression. The prolonged presence of MMPR-5P was important for optimal chemotherapeutic effect. since treatment with iodotubercidin (Iodo T), an inhibitor of MMPR, adenosine kinase, 6 h after MMPR + 6AN administration prevented the prolonged accumulation of MMPR-5P and reversed the regression of CDSF1 tumors. In addition. compared to the PMA-treated group, there was a significant restoration of ATP levels after treatment with Iodo T, In individual PMA-treated CD8F1 tumors the degree of ATP depletion was found to correlate with the degree of tumor shrinkage at 24 h, after tumors had sufficient time to respond to treatment, These results define the timecourse of drug-induced apoptosis in CD8F1 tumors, show that ATP depletion occurs prior to apoptosis and demonstrate that prolonged retention of MMPR-5P is associated with optimal chemotherapy. Collectively, these results suggest that the depletion of ATP by PMA treatment may be a component of the biochemical apoptotic cascade in the CDSF1 tumor.
引用
收藏
页码:376 / 384
页数:9
相关论文
共 48 条
[31]  
Nord LD, 1996, BIOCHEM PHARMACOL, V51, P621
[32]   The role of proteases during apoptosis [J].
Patel, T ;
Gores, GJ ;
Kaufmann, SH .
FASEB JOURNAL, 1996, 10 (05) :587-597
[33]   Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis [J].
Santana, P ;
Pena, LA ;
HaimovitzFriedman, A ;
Martin, S ;
Green, D ;
McLoughlin, M ;
CordonCardo, C ;
Schuchman, EH ;
Fuks, Z ;
Kolesnick, R .
CELL, 1996, 86 (02) :189-199
[34]   OXIDANT INJURY OF CELLS - DNA STRAND-BREAKS ACTIVATE POLYADENOSINE DIPHOSPHATE-RIBOSE POLYMERASE AND LEAD TO DEPLETION OF NICOTINAMIDE ADENINE-DINUCLEOTIDE [J].
SCHRAUFSTATTER, IU ;
HINSHAW, DB ;
HYSLOP, PA ;
SPRAGG, RG ;
COCHRANE, CG .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (04) :1312-1320
[35]   DEVELOPMENT OF APOPTOSIS IN IRRADIATED MURINE TUMORS AS A FUNCTION OF TIME AND DOSE [J].
STEPHENS, LC ;
HUNTER, NR ;
ANG, KK ;
MILAS, L ;
MEYN, RE .
RADIATION RESEARCH, 1993, 135 (01) :75-80
[36]   APOPTOSIS IN IRRADIATED MURINE TUMORS [J].
STEPHENS, LC ;
ANG, KK ;
SCHULTHEISS, TE ;
MILAS, L ;
MEYN, RE .
RADIATION RESEARCH, 1991, 127 (03) :308-316
[37]  
STOLFI RL, 1971, CANCER CHEMOTH REP 1, V55, P239
[38]   Enhanced antitumor activity of an adriamycin plus 5-fluorouracil combination when preceded by biochemical modulation [J].
Stolfi, RL ;
Colofiore, JR ;
Nord, LD ;
Martin, DS .
ANTI-CANCER DRUGS, 1996, 7 (01) :100-104
[39]  
STOLFI RL, 1992, CANCER RES, V52, P4074
[40]  
SWEET S, 1995, CANCER RES, V55, P5164